Skip to content

Comparison the effect of Letrozole with Misoprostol on induction of second trimester abortion in pregnancy

The effect of letrozole with misoprostol on induced abortion in the second trimester

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130626013777N2
Enrollment
86
Registered
2019-02-14
Start date
2019-02-13
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Termination of pregnancy in the second trimester. Medical abortion

Interventions

Intervention 1: Intervention group: 7.5 mg ? letrozole (Manufacturing Iran Hormones Company) prescribed up to three doses at home, the patient was hospitalized on the fourth and Misoprostol 400 microg

Sponsors

?????? ??????? ? ?????? ??????? ???? ????? ?????
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: patients more than 18 years of age Gestational age of 13 to 26 with an indication for termination of pregnancy in medical method Hb above 10 Reason for termination of pregnancy, such as missed abortion; Pregnancy NULL; Therapeutic abortion legal authorization and consent of patients BMI between 25-25

Exclusion criteria

Exclusion criteria: Pain and bleeding Drug sensitivity to misoprostol; Severe anemia Coagulopathy or taking anticoagulants Active liver disease Cardiovascular disease and uncontrolled seizures Adrenal disease history of corticosteroid use

Design outcomes

Primary

MeasureTime frame
Abortion. Timepoint: The start of the intervention up to 24. Method of measurement: Ultrasound.;Time between medication abortion. Timepoint: The start of the intervention up to 24. Method of measurement: hour.;The need for curettage. Timepoint: Seven days after abortion. Method of measurement: Clinical.

Secondary

MeasureTime frame
Side effects. Timepoint: Intervention to 24 hours after administration. Method of measurement: Clinical.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShamsi Abbasalizadeh

Tabriz University of Medical Sciences

lahroudin@gmail.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026